RGLS

Regulus Therapeutics Presentation: Regulus Therapeutics Inc. will have CEO Jay Hagan present at the 2025 Oppenheimer Innovation on the Island Biotech Summit on April 9th, with a live stream and replay available on their investor relations website.

Company Overview: Regulus is a biopharmaceutical company based in San Diego, specializing in innovative medicines targeting microRNAs, supported by a strong pipeline and intellectual property in this field.

Wells Fargo Upgrade: On March 27, 2025, Wells Fargo upgraded Regulus Therapeutics' outlook from Equal-Weight to Overweight, with an average one-year price target suggesting a potential increase of 607.38% from its current price of $1.49/share.

Institutional Ownership Trends: There has been a slight decrease in institutional ownership of Regulus Therapeutics, with total shares owned dropping by 5.63% over the last three months, while some firms like Octagon Capital Advisors have increased their holdings.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Study Results: Regulus Therapeutics Inc. announced positive topline results from its Phase 1b MAD study of farabursen for treating autosomal dominant polycystic kidney disease (ADPKD), showing significant reductions in kidney volume growth and favorable safety profiles among patients receiving the drug.

Market Impact: Following the announcement, Regulus Therapeutics' stock surged by nearly 52%, reflecting investor optimism regarding the drug's efficacy and potential market impact.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Clinical Trial Progress: Regulus Therapeutics announced positive interim results from a Phase 1b clinical trial of farabursen (RGLS8429) for treating autosomal dominant polycystic kidney disease (ADPKD), showing safety, tolerability, and potential efficacy in reducing kidney volume growth.

FDA Collaboration: The company has reached an agreement with the FDA on key components for a Phase 3 pivotal trial aimed at Accelerated Approval, which includes a 12-month endpoint based on kidney volume measurements.

Regulus Therapeutics Announcement: Regulus Therapeutics Inc. will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference on March 11, 2025, at 3:40 p.m. ET, with a live stream available on their website.

Company Overview: Regulus is a biopharmaceutical company based in San Diego, focused on developing innovative medicines targeting microRNAs, supported by a strong intellectual property portfolio.

Company Announcement: Regulus Therapeutics Inc. will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 2:40 p.m. ET, with a live stream available on their website.

About Regulus: Regulus Therapeutics is a biopharmaceutical company based in San Diego, focused on developing innovative medicines targeting microRNAs, supported by a strong intellectual property portfolio.

Surge in Biotech Interest: Several biotech companies, including Silexion Therapeutics and 60 Degrees Pharmaceuticals, are experiencing significant increases in search activity, indicating heightened investor interest potentially linked to clinical developments and FDA approvals.

Recent Clinical Updates: Companies like Tectonic Therapeutics and SAB BIO have reported positive interim data from clinical trials, while others like CARGO Therapeutics are restructuring their operations following safety concerns in their studies.

Regulus Therapeutics Stock Reaction: Regulus Therapeutics shares fell 24% following the release of study results for its ADPKD program, despite positive topline results from an interim analysis of its drug farabursen.

Regulatory Update: The company successfully concluded an End-of-Phase-1 meeting with the FDA, agreeing on key components for a Phase 3 trial aimed at potential accelerated approval.

Positive Clinical Results: Regulus Therapeutics announced promising interim results from its Phase 1b clinical trial of farabursen for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD), showing a reduction in kidney volume growth and favorable safety data.

FDA Meeting Success: The company successfully concluded an End-of-Phase 1 meeting with the FDA, aligning on key components for a Phase 3 pivotal trial that may lead to Accelerated Approval for farabursen.

Investor Conferences Announcement: Regulus Therapeutics Inc. will participate in the Evercore 7th Annual HealthCONx Conference on December 3, 2024, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, with live events available on their investor relations website.

Company Overview and Forward-Looking Statements: Regulus is focused on developing innovative medicines targeting microRNAs and has outlined potential risks and uncertainties regarding its drug development programs, including the RGLS8429 program and its preclinical pipeline.

Q3 Earnings Report: Regulus Therapeutics Inc. reported a net loss of $14.1 million for Q3 2024, an increase from $7.8 million in the previous year, with total operating expenses rising to $15.2 million due to heightened research and development investments.

Future Plans: The company aims to continue advancing its microRNA therapeutic programs while seeking additional funding to support its strategic objectives, expressing confidence in achieving key milestones despite industry challenges.

Real-time Intelligence: Benzinga Pro offers traders the fastest and most accurate stock market intelligence, helping them make informed decisions daily.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and alerts generated by Benzinga reporters.

Investor Conferences Participation: Regulus Therapeutics Inc. will participate in the Wells Fargo Healthcare Conference on September 4, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, with live events available for replay on their website.

Company Overview and Forward-Looking Statements: Regulus focuses on developing innovative medicines targeting microRNAs and has a pipeline supported by strong intellectual property; however, they caution that forward-looking statements about their drug development may not materialize due to various risks and uncertainties.

Novavax (NVAX): Analyst Eric Joseph downgraded Novavax to Sell with a price target of $8.00, while the consensus remains a Hold with a target of $18.00 despite its shares closing at $11.60.

Regulus (RGLS) and Canopy Growth (CGC): Regulus holds a Strong Buy consensus with a price target of $11.20, while Canopy Growth has a Hold rating with a target of C$8.00, as analysts maintain their positions amidst fluctuating share prices.

Clinical Trial Progress: Regulus Therapeutics announced positive topline data from the third cohort of its Phase 1b MAD study for RGLS8429 in treating autosomal dominant polycystic kidney disease (ADPKD), showing significant improvements in kidney function and volume, with plans for an End-of-Phase 1 meeting with the FDA by year-end.

Financial Update: The company reported a cash position of $95.9 million as of June 30, 2024, providing a runway into H1 2026, while also appointing Rekha Garg as Chief Medical Officer and being added to the Russell 3000® and Russell 2000® Indexes.

Company Presentation Announcement: Regulus Therapeutics Inc. will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, at 8:30 a.m. ET, with a replay available for 90 days on their website.

Forward-Looking Statements and Risks: The company issued forward-looking statements regarding its RGLS8429 program and preclinical pipeline, highlighting potential risks and uncertainties that could affect actual results and timelines.

JP Morgan on Sea Limited SE:

• JP Morgan cut the price target for Sea Limited from $84 to $78 and downgraded the stock from Overweight to Neutral.
• Sea shares closed at $75.89, gaining 0.6% on Monday.

Morgan Stanley on Birkenstock Holding plc BIRK:

• Morgan Stanley raised the price target for Birkenstock Holding plc from $44 to $58 and maintained an Equal-Weight rating.
• Birkenstock shares fell 2.8% to close at $59.78 on Monday.

TD Cowen on Credo Technology Group Holding Ltd CRDO:

• TD Cowen boosted Credo Technology Group Holding Ltd's price target from $24 to $35 and upgraded the stock from Hold to Buy.
• Credo Technology shares closed at $27.29, falling 0.7% on Monday.

UBS on Cloudflare, Inc. NET:

• UBS raised the price target for Cloudflare, Inc. from $76 to $82 and upgraded the stock from Sell to Neutral.
• Cloudflare shares rose 0.9% to close at $78.60 on Monday.

Needham on G1 Therapeutics, Inc. GTHX:

• Needham cut G1 Therapeutics' price target from $12 to $6 but maintained a Buy rating.
• G1 Therapeutics shares closed at $2.22, falling 10.5% on Monday.